Phase I Clinical and Pharmacokinetic Study of Bi-weekly Carboplatin/Paclitaxel Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung Cancer

被引：0

作者：

Tsubata, Yukari ^{[1
]}

Okimoto, Tamio ^{[1
]}

Miura, Kiyotaka ^{[1
]}

Karino, Fumi ^{[1
]}

Iwamoto, Shinichi ^{[1
]}

Tada, Mitsuhiro ^{[1
]}

Honda, Takeshi ^{[1
]}

Hamaguchi, Shunichi ^{[1
]}

Ohe, Miki ^{[1
]}

Sutani, Akihisa ^{[1
]}

Kuraki, Takashige ^{[1
]}

Hamada, Akinobu ^{[2
]}

Isobe, Takeshi ^{[1
]}

机构：

[1] Shimane Univ, Dept Internal Med, Div Med Oncol & Resp Med, Fac Med, Izumo, Shimane 6938501, Japan

[2] Natl Canc Ctr, Res Inst, Div Integrat Omics & Bioinformat, Tokyo 104, Japan

来源：

ANTICANCER RESEARCH | 2013年 / 33卷 / 01期

关键词：

Aged patient; elderly; non-small cell lung cancer; chemotherapy; pharmacokinetics; quality of life; carboplatin; paclitaxel; maximum tolerated dose; PACLITAXEL; TRIAL; VINORELBINE; CISPLATIN; GEMCITABINE; THERAPY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: We evaluated the pharmacokinetics and quality of life of elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with bi-weekly carboplatin and paclitaxel chemotherapy, and determined the maximum tolerated dose (MTD) of this treatment. Patients and Methods: Eligible patients had histologically- or cytologically-proven inoperable NSCLC, age of 70 years or older, no prior treatment, and Eastern Cooperative Oncology Group performance status 0-2. Paclitaxel was administered in combination with carboplatin under a bi-weekly schedule. We determined the plasma concentrations of both drugs during therapy. Results: The median patient age was 80 years. Using carboplatin at AUC 3, the MTD of paclitaxel was 100 mg/m(2). Both hematological and non-hematological toxicities were mostly mild and manageable. Although paclitaxel is predominantly metabolized in the liver, clearance was decreased in patients with lower estimated glomerular filtration rate. Conclusion: Bi-weekly treatment, as described here, is feasible for elderly patients as a conventional regimen, particularly in the outpatient setting, due to its lower toxicity.

引用

页码：261 / 266

页数：6

共 22 条

[1] American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].